Aura Biosciences Touts Phase 3 bel-sar Momentum, Eyes Mid-Year Bladder Cancer Data at TD Cowen Conference [Yahoo! Finance]
Aura Biosciences, Inc. (AURA)
Company Research
Source: Yahoo! Finance
Special Protocol Assessment (SPA) , with time to tumor progression as the primary endpoint and top-line data targeted for Q4 2027 (enrollment expected to finish in The company cites a strong Phase 2 signal—patients receiving the full therapeutic regimen had ~ complete cessation of tumor growth versus ~ progression with subtherapeutic dosing—which underpins confidence even as Phase 3 is conservatively powered. Aura expects a mid-year update in bladder cancer from a neoadjuvant study (potentially ~ 15–20 patients ), reporting marked immune activation (e.g., 40x NK and 7x cytolytic CD4 increases) and favorable tolerability with no grade 2/3 adverse events to date. Interested in Aura Biosciences, Inc.? Here are five stocks we like better. 3 Small-Cap Stocks Ready to Deliver Significant Growth Aura Biosciences (NASDAQ:AURA) highlighted progress across its ocular oncology pipeline and provided updates on a parallel effort in bladder cancer during a fireside chat at TD Cowen's 46th
Show less
Read more
Impact Snapshot
Event Time:
AURA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AURA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AURA alerts
High impacting Aura Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
AURA
Earnings
- 11/13/25 - Beat
AURA
Sec Filings
- 3/3/26 - Form 4
- 3/3/26 - Form 4
- 3/3/26 - Form 4
- AURA's page on the SEC website